Focus: Bio-Thera Solutions is a Chinese biotechnology company founded in 2019 specializing in biosimilars targeting oncology and immunology indications. The company has launched two biosimilar products (bevacizumab and ustekinumab) and maintains an active pipeline of 30 programs across oncology, immunology, ophthalmology, and infectious disease.
Profile data last refreshed 18h ago · AI intelligence enriched 2d ago
No open roles listed right now. Follow Bio-Thera Solutions to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Bio-Thera Solutions's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Lead biosimilar candidate targeting VEGF-mediated angiogenesis; bevacizumab is a validated blockbuster MOA with 20-day half-life and linear pharmacokinetics across multiple patient subgroups.
Help build intelligence for Bio-Thera Solutions
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Recently launched ustekinumab biosimilar entering competitive immunology market; lifecycle stage indicates early commercial ramp.
No open positions listed yet.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo